NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT06308575 2025-01-10
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04501705 2024-10-15
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Beijing Sanbo Brain Hospital
Phase NA Recruiting
NCT03801200 2022-02-08
Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC
Hubei Cancer Hospital
Phase 2 Unknown
NCT04216550 2021-02-08
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas
The First Affiliated Hospital of Zhengzhou University
Unknown
NCT04588987 2020-10-19
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
Sun Yat-sen University
Phase 2 Unknown
NCT03567135 2020-03-03
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Fuzhou General Hospital
Unknown
NCT03741244 2019-07-23
TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT
The Second Hospital of Hebei Medical University
Phase 2 Unknown
NCT03390062 2018-01-04
A Study of Apatinib in Recurrent or Recurrent High-grade Glioma
West China Hospital
Phase 2 Unknown
NCT03356600 2017-12-11
Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer
Shanxi Province Cancer Hospital
Phase 2 Unknown